Fulton Breakefield Broenniman LLC Has $9.82 Million Stake in Kenvue Inc. (NYSE:KVUE)

Fulton Breakefield Broenniman LLC reduced its stake in Kenvue Inc. (NYSE:KVUE) by 7.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 455,872 shares of the company’s stock after selling 34,062 shares during the quarter. Fulton Breakefield Broenniman LLC’s holdings in Kenvue were worth $9,815,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Golden State Equity Partners grew its stake in shares of Kenvue by 12.4% during the 4th quarter. Golden State Equity Partners now owns 27,262 shares of the company’s stock worth $587,000 after acquiring an additional 3,004 shares in the last quarter. Truist Financial Corp grew its stake in shares of Kenvue by 55.4% during the 4th quarter. Truist Financial Corp now owns 833,310 shares of the company’s stock worth $17,941,000 after acquiring an additional 297,178 shares in the last quarter. Bahl & Gaynor Inc. grew its stake in shares of Kenvue by 4.8% during the 4th quarter. Bahl & Gaynor Inc. now owns 262,992 shares of the company’s stock worth $5,662,000 after acquiring an additional 12,082 shares in the last quarter. Jackson Hole Capital Partners LLC bought a new position in shares of Kenvue in the fourth quarter valued at $481,000. Finally, State of New Jersey Common Pension Fund D grew its stake in shares of Kenvue by 10.7% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 966,624 shares of the company’s stock valued at $20,811,000 after buying an additional 93,478 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

KVUE opened at $18.86 on Friday. Kenvue Inc. has a fifty-two week low of $17.82 and a fifty-two week high of $27.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. The stock has a fifty day moving average of $19.84 and a 200-day moving average of $20.13.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. On average, research analysts forecast that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.24%. The ex-dividend date is Tuesday, May 7th.

Analyst Ratings Changes

Several equities analysts recently weighed in on KVUE shares. Sanford C. Bernstein started coverage on shares of Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price for the company. William Blair started coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. The Goldman Sachs Group started coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price for the company. Finally, Royal Bank of Canada reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $24.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.